These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11086225)

  • 1. Development of vaccines for prevention of botulism.
    Byrne MP; Smith LA
    Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
    Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
    Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines against botulism.
    Karalewitz AP; Barbieri JT
    Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulism and vaccines for its prevention.
    Smith LA
    Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin vaccines: past, present, and future.
    Smith LA; Rusnak JM
    Crit Rev Immunol; 2007; 27(4):303-18. PubMed ID: 18197811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
    Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
    Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
    Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targets in the search for preventive and therapeutic agents for botulism.
    Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
    Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of recombinant vaccines for botulinum neurotoxin.
    Smith LA
    Toxicon; 1998 Nov; 36(11):1539-48. PubMed ID: 9792170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of recombinant botulism antigens: a review of expression systems.
    Moreira GM; Cunha CE; Salvarani FM; Gonçalves LA; Pires PS; Conceição FR; Lobato FC
    Anaerobe; 2014 Aug; 28():130-6. PubMed ID: 24930432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
    Clayton MA; Clayton JM; Brown DR; Middlebrook JL
    Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
    Lee JS; Pushko P; Parker MD; Dertzbaugh MT; Smith LA; Smith JF
    Infect Immun; 2001 Sep; 69(9):5709-15. PubMed ID: 11500447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.